Literature DB >> 25781190

miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy.

Satish K Raut1, Akhilesh Kumar1, Gurinder B Singh1, Uma Nahar2, Vibhuti Sharma2, Anupam Mittal3, Rajni Sharma1, Madhu Khullar1.   

Abstract

AIM: Cardiac hypertrophy and myocardial fibrosis significantly contribute to the pathogenesis of diabetic cardiomyopathy (DCM). Altered expression of several genes and their regulation by microRNAs has been reported in hypertrophied failing hearts. This study aims to examine the role of Cdc42, Pak1, and miR-30c in the pathogenesis of cardiac hypertrophy in DCM.
METHODS: DCM was induced in Wistar rats by low-dose streptozotocin-high-fat diet for 12 weeks. Cardiac expression of Cdc42, Pak1 and miR-30c, and hypertrophy markers (ANP and β-MHC) was studied in DCM vs control rats and in high-glucose (HG)-treated H9c2 cardiomyocytes.
RESULTS: Diabetic rats showed cardiomyocyte hypertrophy, increased heart-to-body weight ratio, and an increased expression of ANP and β-MHC. Cardiac expression of Cdc42 and Pak1 genes was increased in diabetic hearts and in HG-treated cardiomyocytes. miR-30c was identified to target Cdc42 and Pak1 genes, and cardiac miR-30c expression was found to be decreased in DCM rats, patients with DCM, and in HG-treated cardiomyocytes. miR-30c overexpression decreased Cdc42 and Pak1 genes and attenuated HG-induced cardiomyocyte hypertrophy, whereas miR-30c inhibition increased Cdc42 and Pak1 gene expression and myocyte hypertrophy in HG-treated cardiomyocytes.
CONCLUSION: Downregulation of miR-30c mediates prohypertrophic effects of hyperglycemia in DCM by upregulation of Cdc42 and Pak1 genes.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Cardiac hypertrophy; Cdc42; Diabetic cardiomyopathy; Pak1; miR-30c

Mesh:

Substances:

Year:  2015        PMID: 25781190     DOI: 10.1111/1755-5922.12113

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  32 in total

1.  Sexual dimorphism in the fetal cardiac response to maternal nutrient restriction.

Authors:  Sribalasubashini Muralimanoharan; Cun Li; Ernesto S Nakayasu; Cameron P Casey; Thomas O Metz; Peter W Nathanielsz; Alina Maloyan
Journal:  J Mol Cell Cardiol       Date:  2017-06-19       Impact factor: 5.000

Review 2.  LncRNAs and miRs as epigenetic signatures in diabetic cardiac fibrosis: new advances and perspectives.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Endocrine       Date:  2018-07-27       Impact factor: 3.633

3.  Exploring miRNA-mRNA regulatory network in cardiac pathology in Na+/H+ exchanger isoform 1 transgenic mice.

Authors:  Jin Xue; Dan Zhou; Orit Poulsen; Iain Hartley; Toshihiro Imamura; Edward X Xie; Gabriel G Haddad
Journal:  Physiol Genomics       Date:  2018-07-20       Impact factor: 3.107

4.  Role of microRNAs in the pathogenesis of diabetic cardiomyopathy.

Authors:  Xinyu Liu; Shixue Liu
Journal:  Biomed Rep       Date:  2017-01-12

5.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

6.  MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy.

Authors:  Gurinder Bir Singh; Satish K Raut; Sanskriti Khanna; Akhilesh Kumar; Saurabh Sharma; Rishikesh Prasad; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-09-30       Impact factor: 3.396

7.  Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.

Authors:  Bhawna Rastogi; Satish K Raut; Naresh K Panda; Vidya Rattan; Bishan D Radotra; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-03-18       Impact factor: 3.396

Review 8.  Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.

Authors:  Brahmanaidu Parim; V V Sathibabu Uddandrao; Ganapathy Saravanan
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

9.  miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy.

Authors:  Satish K Raut; Gurinder B Singh; Bhawna Rastogi; Uma Nahar Saikia; Anupam Mittal; Nilambra Dogra; Sandeep Singh; Rishikesh Prasad; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-05-25       Impact factor: 3.396

10.  MiR-144 affects proliferation and apoptosis of high glucose-induced AC16 cardiomyocytes by regulating CTRP3/JNK signaling.

Authors:  Yanling Song; Huade Mai; Yunyun Lin; Yachun Wang; Xiaoxi Wang; Shenhong Gu
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.